Introduction {#s1}
============

*Staphylococcus aureus* (*S. aureus*) is a major pathogen of human infection that causes diseases ranging from minor skin infections to severe bacteremia, necrotizing pneumonia, and life-threatening sepsis ([@B1]--[@B3]), and thus is a major global threat to human health. *S. aureus* can colonize multifarious body regions, including the anterior nares ([@B4]), skin ([@B5]), intestinal tract ([@B6]), oropharynx ([@B7]), and so on. Colonization is a crucial risk factor for the subsequent development of infections ([@B8]). Specifically, the importance of *S. aureus* fecal colonization was described as early as 1960 ([@B9]), in a study that demonstrated rectal carriage of *S. aureus* earlier than from the nose or throat. Subsequently, several studies have confirmed the clinical importance of *S. aureus* fecal carriage ([@B10], [@B11]). Additionally, *S. aureus* fecal carriage may contribute to environmental contamination ([@B12]), which can lead to nosocomial transmission and infection. Previous studies have reported fecal carriage of *S. aureus* in adults from Nigeria ([@B13]) and India ([@B14]), and a recent study investigated intestinal colonization by *S. aureus* and *Clostridium difficile* in healthy adult fecal samples from China ([@B15]), and a few studies have reported on *S. aureus* isolated from pediatric patients\' feces samples in China.

Multilocus sequence typing (MLST) has become one of the most popular methods for evaluating *S. aureus* strains; however, only limited MLST studies of *S. aureus* from stool samples are available. Methicillin-sensitive (MSSA) strains ST30, ST398, and ST133 were detected from 100 healthy human fecal samples in Spain ([@B16]), while ST15, ST188, and ST59 were identified in six *S. aureus* isolates from stool specimens of diarrheal infants ([@B17]). Unfortunately, the diversity of molecular *S. aureus* types in these studies was limited due to the relatively small population size, which may have led to misinterpretation or inaccurate conclusions to be drawn regarding *S. aureus* colonization in fecal samples.

In addition to molecular characterization, antibiotic resistance, notably regarding the emergence and evolution of multi-drug-resistant (MDR) *S. aureus*, has become a major focal point in research across the world. Methicillin-resistant *S. aureus* (MRSA), which begins with resistance to methicillin or most β-lactam antibiotics and gradually develops co-resistance to vancomycin ([@B18], [@B19]), limits the use of alternative anti-infective drugs and threatens patient\'s health. Hence, drug resistance should be closely monitored to provide the basis for clinical antibacterial infection treatment, including exploring antibiotic resistance of *S. aureus* isolated from fecal samples.

Thus, the aims of this investigation were to evaluate the prevalence, molecular genotyping and antibiotic resistance of *S. aureus* isolated from pediatric patients\' fecal samples in Southern China.

Materials and Methods {#s2}
=====================

Ethics
------

All patients were recruited voluntarily and provided informed consent from the participants or the guardians. The study was approved by the research ethics committee of the Guangzhou women and children\'s medical center (registration no. 2016081029).

Bacterial Isolates and Data Collection
--------------------------------------

This study enrolled children from three medical centers in Southern China between August and November 2018, including Guangzhou Women and Children\'s Medical Center (Tianhe District, central Guangzhou), Guangzhou Children\'s Hospital (Yuexiu District, western Guangzhou), and Zengcheng Maternity and Children\'s Health Care Center (Zengcheng District, northern Guangzhou). A total of 2059 non-duplicate pediatric stool samples (1308 outpatients and 751 inpatients) were collected. Approximately 20 mg of stool sample was streaked onto a selective mannitol salt agar medium (Hope Bio-technology, Qingdao, China) within 4 h of sample collection, and incubated in a humidified atmosphere at 37°C with 5% CO~2~ for 24 h. Suspected *S. aureus* colonies from each sample were evaluated based on morphology and sub-cultured on Columbia Blood Agar Medium (Detgerm Microbiology Technology, Guangzhou, China) ([@B20]). All isolates were further identified for their species assignment by the automated VITEK MS (bioMérieux, Marcy-l\'Étoile, France). Identified *S. aureus* was further confirmed by detecting *femB* ([@B21]). We also collected a range of clinical information from the laboratory information system, including gender, age, types, diagnosis, and fecal occult blood test (FOBT). Accordingly, the patients were classified into six age groups: 0--28 days, newborn; 28 days--3 months, young infant; 3 months--1 year, older infant; 1--3 years, child; 3--6 years, pre-school age; 6--18 years, school age and puberty ([@B22], [@B23]). Among these patients, the oldest was 17 years old, the youngest was 1 day, and the median age was 10 months and 23 days.

Antibiotic Susceptibility Tests
-------------------------------

Antibiotic susceptibility for 15 antibiotics (penicillin, oxacillin, gentamicin, rifampicin, levofloxacin, ciprofloxacin, trimethoprim/sulfamethoxazole, clindamycin, erythromycin, macrodantin, linezolid, vancomycin, quinoputin/dafutin, tetracycline, and tigecycline) was detected by VITEK 2 AST-GP67 cards (bioMérieux) using the automated VITEK2 compact system (bioMérieux). Antibiotic minimum inhibitory concentration (MIC) was determined according to the published guidelines ([@B24]). The quality control strain used in antibiotic susceptibility analysis was *S. aureus* ATCC 29213. MRSA was defined as an oxacillin-resistant isolate, and multidrug-resistant (MDR) isolates were identified as isolates with resistance to three or more non-β-lactam antibiotics ([@B25]).

DNA Extraction
--------------

Total DNA was extracted from 1.0 ml of nutrient broth medium culture grown overnight. After centrifugation, the supernatant was discarded and the *S. aureus* isolates were resuspended in 200 μl of enzymatic lysis buffer (Sangon Biotech, Shanghai, China). Subsequently, *S. aureus* solution was incubated at 37°C for 30 min with 3 μl of lysostaphin (Sigma-Aldrich, Shanghai, China), mixed with 200 μl of Buffer BD (Sangon Biotech), and 200 μl of 100% ethanol (Guangzhou Chemical Reagent Factory, Guangzhou, China), and then transferred to an absorbing column (Sangon Biotech). Next, the Ezup Column Bacterial Genomic DNA Extraction Kit (Sangon Biotech) was used in accordance with the manufacturer\'s instructions.

PCR Detection of *femB* and *mecA*
----------------------------------

The *femB* gene plays an important role in formatting the pentaglycine bridges that stabilize peptidoglycan chains in *S. aureus*, while the *mecA* gene is the most important cause of *S. aureus* resistance to oxacillin ([@B26]). Thus, to further confirm the presence *S. aureus* and MRSA, we detected the expression of *femB* and *mecA* by PCR. The primers used for *femB* and *mecA* genes were described previously ([@B27]), and extracted DNA was amplified using TaqTM (Takara, Tokyo, Japan) following the manufacturer\'s instructions. Following amplification and extension, the PCR amplicons were separated on 1% agarose gels stained with ethidium bromide and visualized under UV illumination (TEX-20 M, Life Technologies, Carlsbad, USA).

MLST Typing
-----------

All isolates were analyzed by multilocus sequence typing (MLST) according to a previously published procedure ([@B28]). The PCR products were purified and sequenced by a commercial sequencing company (Beijing Genomics Institute, Shenzhen, China). DNA sequencing of seven housekeeping genes (*arc*C, *aroE, glpF, gmk, pta, tpi*, and *yqiL*) was used for MLST analysis. Sequence types (STs) were determined by searching the *S. aureus* MLST database (<https://pubmlst.org/saureus/>), which included new emerging MLST alleles and MLST types. Clonal complex (CC) analysis was conducted using the eBURST v.3 programme (<https://www.mlst.net/eburst/>) according to our previously described protocol ([@B27]). Based on STs, a UPGMA dendrogram was constructed with START2.

Statistical Analysis
--------------------

Statistical analyses were carried out with SPSS software 20 (SPSS Inc., Chicago, USA). The chi-square (χ^2^) test or Fisher\'s exact test were applied to dichotomous or categorical variables, which were described as frequencies and proportions. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Prevalence of *S. aureus* and MRSA Was Associated With Clinical Features
------------------------------------------------------------------------

A total of 2059 fecal samples were collected from pediatric patients in three hospitals, from which 412 *S. aureus* and 93 MRSA isolates were identified. The overall colonization prevalence of *S. aureus* and MRSA were 20.0 and 4.5%, respectively. Accordingly, we classified the 2059 patients into two groups consisting of those that were *S. aureus* positive (*n* = 412) and negative (*n* = 1,647), to analyze the correlation of *S. aureus* fecal carriage with different clinical features. As shown in [Table 1](#T1){ref-type="table"}, the fecal carriage of *S. aureus* was not associated with patient gender (*P* = 0.149); however, it was positively correlated with outpatient status and gastroenteritis diagnosis (*P* \< 0.01). We also observed a positive relationship between *S. aureus* and different age groups. The minimum *S. aureus* carriage rate was in newborn patients (7.3%), while the maximum rate was in infant patients (young infants, 26.6% and older infants 26.3%), after which the carriage rate gradually descended with increasing age of the patients ([Table 1](#T1){ref-type="table"}). In addition, we observed a positive correlation between FOBT results and *S. aureus* carriage (*P* \< 0.01, [Table 1](#T1){ref-type="table"}).

###### 

Correlation of fecal carriage of *S. aureus* in pediatric patients with different clinical features.

                                             ***S. aureus***                          
  ---------------- ------------------ ------ ----------------- ------------- -------- ------------------------------------------------
  Total patients                      2059   412 (20.0)        1647 (80.0)            
  Gender           Males              1215   256 (21.1)        959 (78.9)    2.082    0.149
                   Females            844    156 (18.5)        688 (81.5)             
  Status           Outpatients        1308   344 (26.3)        964 (73.7)    88.643   \<0.001[^\*\*^](#TN1){ref-type="table-fn"}
                   Inpatients         751    68 (9.1)          683 (90.9)             
  Diagnosis        Gastroenteritis    1242   319 (25.7)        923 (74.3)    62.974   \<0.001[^\*\*^](#TN1){ref-type="table-fn"}
                   Others             817    93 (11.4)         724 (88.6)             
  Age              0--28 days         205    15 (7.3)          190 (92.7)    55.629   \<0.001[^\*\*^](#TN1){ref-type="table-fn"}
                   28 days−3 months   241    64 (26.6)         177 (73.4)             
                   3 months−1 year    726    191 (26.3)        535 (73.7)             
                   1--3 years         484    85 (17.6)         399 (82.4)             
                   3--6 years         240    35 (14.6)         205 (85.7)             
                   6--18 years        163    22 (13.5)         141 (86.5)             
  FOBT             Positive           784    210 (26.8)        574 (73.2)    36.319   \<0.001**[^\*\*^](#TN1){ref-type="table-fn"}**
                   Negative           1275   202 (15.8)        1073 (84.2)            

*+: S. aureus-positive group; --: S. aureus-negative group. Clinicopathological features were assessed using the chi-square test*,

*P \< 0.01*.

Subsequently we divided the 412 positive *S. aureus* patients into two groups, MRSA (*n* = 93) and MSSA (*n* = 319), to explore the relationship of MRSA and clinical features. However, we found that MRSA was significantly correlated with inpatient status (*P* = 0.002), and not gender, age, or FOBT results ([Table 2](#T2){ref-type="table"}).

###### 

Correlation of MRSA in pediatric patients\' fecal samples with different clinical features.

  **Variable**     **Groups**         ***S. aureus***   **MRSA**    **MSSA**     **χ^2^**   ***P***
  ---------------- ------------------ ----------------- ----------- ------------ ---------- ----------------------------------------------
  Total patients                      412               93 (22.6)   319 (77.4)              
  Gender           Males              256               60 (23.4)   196 (76.6)   0.289      0.591
                   Females            156               33 (21.2)   123 (78.8)              
  Status           Outpatients        344               68 (19.8)   276 (80.2)   9.385      0.002**[^\*\*^](#TN2){ref-type="table-fn"}**
                   Inpatients         68                25 (36.8)   43 (63.2)               
  Age              0--28 days         15                5 (33.3)    10 (66.7)    1.763      0.881
                   28 days−3 months   64                15 (23.4)   49 (76.6)               
                   3 months−1 year    191               39 (20.4)   152 (79.6)              
                   1--3 years         85                20 (23.5)   65 (76.5)               
                   3--6 years         35                8 (22.9)    27 (77.1)               
                   6--18 years        22                6 (27.3)    16 (72.7)               
  FOBT             Positive           210               40 (19.0)   170 (81.0)   3.045      0.081
                   Negative           202               53 (26.2)   149 (73.8)              

*MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus. Clinicopathological features were assessed using the chi-square test*,

*P \< 0.01*.

Antibiotic Susceptibility of *S. aureus* and MRSA
-------------------------------------------------

The antibiotic susceptibility results for the 412 *S. aureus* isolates according to MLST are presented in [Table 3](#T3){ref-type="table"}. All 93 MRSA strains were resistant to cefoxitin screening and carried the *mec*A gene. The *S. aureus* strains exhibited highest rate of resistance to penicillin (PEN, 84.2%), followed by erythromycin (ERY, 38.8%), clindamycin (CLI, 35.9%), tetracycline (TE, 14.6%), and sulfamethoxazole-trimethoprim (SXT, 6.1%). The resistance rates of antibiotics were lower for gentamicin (GEN, 2.7%), levofloxacin (LEV, 1.9%), ciprofloxacin (CIP, 1.9%), and rifampicin (RIF, 0.7%); however, all isolates were susceptible to macrodantin, linezolid, vancomycin, dalfopristin/quinupristin (QDA), and tigecycline. Compared to the MSSA group, the MRSA group had significantly higher rates of resistance to PEN (*P* \< 0.01), ERY (*P* \< 0.01), CLI (*P* \< 0.01), and TE (*P* = 0.03) and intermediate resistance to RIF (*P* \< 0.01). Although 22.8% of all strains exhibited MDR, the MRSA group had a significantly higher rate (74.2%) compared to that of the MSSA group (7.8%) (*P* \< 0.01).

###### 

ntibiotic susceptibility of S. aureus and MRSA isolates from pediatric patients\' feces.

  **Antibiotic**   ***S. aureus*** **(*****n*** **=** **412)**   **MRSA (*****n*** **=** **93)**   **MSSA (*****n*** **=** **319)**   ***P*[^***a***^](#TN3){ref-type="table-fn"}**                           
  ---------------- --------------------------------------------- --------------------------------- ---------------------------------- ----------------------------------------------- ------------ ---------- ---------------------------------------------------------------------------
  Penicillin       347 (84.2)                                    0 (0.0)                           93 (100)                           0 (0.0)                                         254 (79.6)   0 (0.0)    \<0.01[^\*\*^](#TN5){ref-type="table-fn"}
  Gentamicin       11 (2.7)                                      4 (1.0)                           2 (2.2)                            2 (2.2)                                         9 (2.8)      2 (0.6)    1.00
  Rifampicin       3 (0.7)                                       43 (10.4)                         2 (2.2)                            27 (29.0)                                       1 (0.3)      17 (5.3)   \<0.01[^b^](#TN4){ref-type="table-fn"}[^\*\*^](#TN5){ref-type="table-fn"}
  Levofloxacin     8 (1.9)                                       0 (0.0)                           4 (4.3)                            0 (0.0)                                         4 (1.3)      0 (0.0)    0.148
  Ciprofloxacin    8 (1.9)                                       1 (0.2)                           4 (4.3)                            0 (0.0)                                         4 (1.3)      1 (0.3)    0.149
  SXT              25 (6.1)                                      0 (0.0)                           2 (2.2)                            0 (0.0)                                         23 (7.2)     0 (0.0)    0.072
  Clindamycin      148 (35.9)                                    0 (0.0)                           67 (72)                            0 (0.0)                                         81 (25.4)    0 (0.0)    \<0.01[^\*\*^](#TN5){ref-type="table-fn"}
  Erythromycin     160 (38.8)                                    1 (0.2)                           67 (72)                            0 (0.0)                                         93 (29.2)    1 (0.3)    \<0.01[^\*\*^](#TN5){ref-type="table-fn"}
  Macrodantin      0 (0.0)                                       0 (0.0)                           0 (0.0)                            0 (0.0)                                         0 (0.0)      0 (0.0)    NA
  Linezolid        0 (0.0)                                       0 (0.0)                           0 (0.0)                            0 (0.0)                                         0 (0.0)      0 (0.0)    NA
  Vancomycin       0 (0.0)                                       0 (0.0)                           0 (0.0)                            0 (0.0)                                         0 (0.0)      0 (0.0)    NA
  QDA              0 (0.0)                                       0 (0.0)                           0 (0.0)                            0 (0.0)                                         0 (0.0)      0 (0.0)    NA
  Tetracycline     60 (14.6)                                     0 (0.0)                           20 (21.5)                          0 (0.0)                                         40 (12.5)    0 (0.0)    0.03[^\*^](#TN6){ref-type="table-fn"}
  Tigecycline      0 (0.0)                                       0 (0.0)                           0 (0.0)                            0 (0.0)                                         0 (0.0)      0 (0.0)    NA

*SXT, trimethoprim/sulfamethoxazole; QDA, dalfopristin/quinupristin. R, Resistant; I, Intermediate; NA, not applicable*.

Antibiotic resistance of MRSA vs. MSSA by chi-squared test (two-sided);

*Rifampicin intermediate of MRSA vs. MSSA by chi-squared test (two-sided)*,

*P \< 0.01*,

*P \< 0.05*.

Molecular Characterization of *S. aureus*
-----------------------------------------

According to the results of the MLST method, 76 unique STs were identified among 412 *S. aureus* isolates, including 25 novel STs. Based on eBURST analysis, the 76 STs were classified into 28 CCs, including 14 groups and 14 singletons ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). The three most abundant STs among all *S. aureus* isolates were ST188 (12.9%), ST45 (12.1%), and ST59 (10.0%), comprising 35% of all isolates. Among the MRSA group, the three most abundant STs were ST59 (37.6%), ST45 (35.5%), and ST1 (5.4%), comprising 78.5% of all strains. Among MSSA group, ST188 (16.0%), ST6 (9.7%), and ST15 (8.5%) were the three prevalent STs. Further, the most common CCs among all strains were CC188, CC45, and CC59, representing 39.6% of all clones. Specifically, within the MRSA group, CC59 (41.9%), CC45 (35.5%), and CC1 (6.5%) were the three most abundant CCs, while in the MSSA group, the most common clone was CC188 (17.9%), followed by CC5 (11.6%) and CC6 (11.0%) ([Table 4](#T4){ref-type="table"}).

![Auto-edited eBURST diagram of 412 *S. aureus* isolates based on the MLST data. The auto-edited eBURST diagram produced using 6/7 group definition shows 76 STs, including 14 groups and 14 singletons. Each dot implies an MLST ST and the dot area indicates the prevalence of the ST in the MLST data of this study. The linked clusters within the population snapshot should represent clonal complexes, and the primary founders and subgroup founders of these linked clusters are colored blue and yellow.](fmed-07-00127-g0001){#F1}

![START2 analysis, genotypes, and drug resistances of *Staphylococcus aureus* isolates. STs, sequence types; CCs, clonal complexes; Each ST randomly selected one isolate as shown above. PEN, penicillin; GEN, gentamicin; RIF, rifampicin; LEV, levofloxacin; CIP, ciprofloxacin; SXT, sulfamethoxazole-trimethoprim; CLI, clindamycin; ERY, erythrocin; TE, tetracycline; MDR, multidrug resistance, representing antibiotic resistance of non β-lactamase. **\***Representing newly assigned STs. ^**\#**^Representing 16 STs that each had more than three strains. ^a^Resistance and intermediary resistance of RIF. Different colors represent different clonal complexes.](fmed-07-00127-g0002){#F2}

###### 

Genotype ranking of *S. aureus* isolated from pediatric patients.

  **Rank**   ***S. aureus*** **(*****n*** **=** **412)**   **MRSA (*****n*** **=** **93)**   **MSSA (*****n*** **=** **319)**                                                                                     
  ---------- --------------------------------------------- --------------------------------- ---------------------------------- ------------ ------- ----------- ------- ----------- ------- ------------ ------- ------------
  1          ST188                                         53 (12.9)                         CC188                              60 (14.6)    ST59    35 (37.6)   CC59    39 (41.9)   ST188   51 (16.0)    CC188   57 (17.9)
  2          ST45                                          50 (12.1)                         CC45                               55 (13.3)    ST45    33 (35.5)   CC45    33 (35.5)   ST6     31 (9.7)     CC5     37 (11.6)
  3          ST59                                          41 (10.0)                         CC59                               48 (11.7)    ST1     5 (5.4)     CC1     6 (6.5)     ST15    27 (8.5)     CC6     35 (11.0)
  4          ST6                                           34 (8.3)                          CC5                                39 (9.5)     ST188   2 (2.2)     CC188   3 (3.2)     ST5     22 (6.9)     CC15    31 (9.7)
  5          ST15                                          27 (6.6)                          CC6                                37 (9.0)     ST6     2 (2.2)     CC5     2 (2.2)     ST45    17 (5.3)     CC7     26 (8.2)
  6          ST5                                           24 (5.8)                          CC15                               31 (7.5)     ST5     2 (2.2)     CC6     2 (2.2)     ST398   17 (5.3)     CC398   24 (7.5)
  7          ST398                                         19 (4.6)                          CC7                                27 (6.6)     ST398   2 (2.2)     CC398   2 (2.2)     ST7     17 (5.3)     CC45    22 (6.9)
  8          ST7                                           18 (4.4)                          CC398                              26 (6.3)     ST338   2 (2.2)     CC630   2 (2.2)     ST30    14 (4.4)     CC30    14 (4.4)
  Total                                                    266 (64.6)                                                           323 (78.4)           83 (89.2)           89 (95.7)           196 (61.4)           246 (77.1)

As shown in [Figure 2](#F2){ref-type="fig"}, there were 25 newly assigned STs (ST5307 to ST5330, and ST5353) in this study, of which many were single-locus variants (SLVs). Among the 25 novel STs, 26 strains were identified, including 2 MRSA and 24 MSSA isolates; both MRSA isolates belonged to CC59, and the most abundant CC in the MSSA groups was CC188. Finally, we identified 18 novel SLVs in seven housekeeping genes, which were subsequently assigned as new alleles ([Table S1](#SM1){ref-type="supplementary-material"}).

Association of Antibiotic Resistance With Specific *S. aureus* Sequence Types
-----------------------------------------------------------------------------

When analyzing the correlation between antibiotic resistance profiles and unique sequence types (STs) in genotypes of the *S. aureus* isolates, 16 STs each had more than three strains that were selected in this study. Some specific STs were determined to be closely associated with certain antibiotic resistance patterns, while some exhibited high sensitivity. As shown in [Figure 2](#F2){ref-type="fig"} and [Figure S1](#SM2){ref-type="supplementary-material"}, all ST338, ST25, ST30, and ST1281 isolates were resistant to PEN, while ST72, ST950, and ST965 showed high sensitivity to PEN. However, ST950 and ST965 showed high resistance to CLI and ERY, yet were sensitive to all other antibiotics, with an MDR rate of 0%, similar to the MDR rate of ST1281 and ST15. Similarly, ST188, with the largest number of strain types and largest antibiotic resistance coverage, had a very low MDR rate (3.8%). All ST30 and ST338 isolates were resistant to ERY and CLI. ST59, which belongs to CC59 with ST338, also showed a high resistance rate (78%) to ERY and CLI. Additionally, ST59 and ST338 had a higher rate of resistance to TE, with the two highest MDR rates of 75.6 and 60.0%, respectively. In addition to the STs mentioned above, ST7 exhibited the highest resistance rate (61.1%) to TE, while ST45, another predominant ST in the MRSA isolate group, had the highest resistance and intermediate resistance rate (84.0%) to RIF ([Figure 2](#F2){ref-type="fig"} and [Figure S1](#SM2){ref-type="supplementary-material"}).

Discussion {#s4}
==========

*S. aureus* fecal carriage may contribute to environmental contamination, facilitate nosocomial transmission, and promote human disease development. Moreover, fecal carriage of *S. aureus* among children is more likely to cause disease infection due to their immature and underdeveloped immune system ([@B29]). Since *S. aureus* fecal colonization has been identified as a risk factor for infection disease development ([@B30]), our findings may serve to advance the current understanding regarding *S. aureus* fecal colonization dynamics and prevention of *S. aureus* infection.

In this study, the *S. aureus* fecal carriage rate was determined to be 20.0% in pediatric patients from Guangzhou, while the MRSA carriage rate was 4.5%. These results agree with the reported prevalence of pooled estimates for *S. aureus* and MRSA fecal carriage rates (16.8--36.3%, 0.7--27.0%, respectively) ([@B30]). However, the prevalence of *S. aureus* in this study was higher than that reported from participants with nosocomial diarrhea in Germany (7%) ([@B31]) compared to healthy adults in China (3.51%) ([@B15]), but was lower than that reported in a previous Nigerian study (31.7%) ([@B13]). Moreover, in China, the prevalence of MRSA nasal colonization in children between 2005 and 2015 was 4.4% ([@B32]), similar to the 4.5% carriage rate detected in our study, but slightly higher than a previous study in American children with cancer (2.9%) ([@B33]). Although the prevalence of *S. aureus* and MRSA is dynamic due to differences in geographical regions, age, gender, and health status, future studies continue to be warranted to better characterize the cause of these differences.

In our study, the fecal carriage of *S. aureus* was positively correlated with outpatient status and gastroenteritis diagnosis. Pediatric gastroenteritis primarily manifests as abdominal pain, diarrhea, and vomiting, and these patients comprise the majority of outpatients. Moreover, *S. aureus* has been described as the most common global causative pathogen of food-borne illness, while studies have reported it to be associated with infantile diarrhea ([@B17]), corresponding with our observed positive correlation between *S. aureus* fecal carriage and gastroenteritis in children. In addition, our study found that fecal *S. aureus* colonization was lowest during the first 4 weeks of life, after which it increased rapidly during the first year, followed by a gradual decline until 17 years of age. This may be explained by the underdeveloped intestinal function and microbiota composition in newborn patients. With improved intestinal function and increased diversity of intestinal microbes, *S. aureus* colonization increased within the following year. Further, human milk oligosaccharides have been suggested to be a strong contributor to bacterial reproduction in the infant gut and to stimulate *S. aureus* growth ([@B34]), providing an important function for breastfeeding in early life. Subsequently, with the consumption of a comprehensive diet and enhanced immune function, the fecal carriage of *S. aureus* decreases with increasing age. Additionally, within this study, *S. aureus* fecal carriage was higher in patients that tested FOBT positive, which may be explained by virulence factors, especially staphylococcal enterotoxins, produced by *S. aureus*, causing intestinal damage that leads to intestinal bleeding. However, this hypothesis requires further validation.

We also determined that fecal carriage of MRSA was positively associated with inpatients status as hospitalized patients are more likely to be infected with MRSA ([@B35]). Interestingly, 7 of the 68 hospitalized patients with *S. aureus* in their stool also had it within in their sputum or alveolar lavage fluid, demonstrating similar antibiotic susceptibility patterns, including 2 MRSA and 5 MSSA isolates (data not shown). This may suggest that the *S. aureus* isolated from stool sample was consistent with the source in the sputum or alveolar lavage fluid, and fecal carriage of *S. aureus* may be associated with infection in other parts of the body.

Based on the MLST results, 412 *S. aureus* isolates were divided into 76 STs, with fewer MRSA isolates (14 STs) than MSSA isolates (69 STs), indicating that MRSA isolates were more genetically stable than MSSA isolates. The most commonly reported *S. aureus* isolates in China are diverse and include ST1 ([@B36]), ST6 ([@B20]), ST5 ([@B37]), and ST188 ([@B38]) according to different regions, ages, and resources. Similarly, many different MSSA isolates have been identified throughout China, including ST7 and ST188 ([@B39]). In our study, ST188, ST6, and ST15 were the most frequently observed STs in the MSSA group. ST188 was reported as a major cause of childhood infections in China, due to its high adhesion and biofilm formation ability ([@B38]). In addition, ST15 and ST188 were the two most prevalent clones isolated from infantile diarrhea fecal samples ([@B17]). Although the types of MSSA strains are diverse, the most abundant ones have not changed significantly among children in China.

MRSA strains demonstrated strong homology with the prevalent clones in this study, which were determined to be ST59 (37.6%) and ST45 (35.5%). This result was consistent with a previous study reported by Ding et al. in Chinese children ([@B40]). ST59, a predominant MRSA clone causing CA-MRSA infections among children ([@B41]), was not only predominant in Chinese cities, including Shanghai ([@B39]), Sichuan ([@B42]), and Taiwan ([@B43]), but also is considered to be a prevalent isolate throughout the Asia-Pacific region ([@B44]). It is worth noting that ST45, the second most prevalent MRSA strain, has an increased carriage rate in children, compared to 18.8% for the MRSA isolated in our previous study ([@B27]). ST45, known as a Berlin clone, was also a common isolate throughout European countries, and has now spread to Australia ([@B45]), Singapore ([@B46]), and China ([@B41]). Further, previous studies from Shanghai have shown that ST239 was the most frequent MRSA clone between 2005 and 2010 ([@B47]), which was replaced by the increasingly abundant ST5, ST59, and ST398 clones between 2008 and 2017 ([@B48]). However, ST239 was not identified in our study, and ST5 and ST398 only accounted for 2.2% of MRSA isolates. Alternatively, ST45 and ST59 were not only the two dominant clones in the MRSA group, but also the second and the third most abundant clones in all *S. aureus* isolates. ST45-MRSA is attributed to the acquisition of *mecA* by a MSSA clone in the community ([@B49]). Therefore, our results suggest that ST45 would alter the MRSA clone structure in this region of China, allowing for the development of additionally prominent clones in Chinese children, such as ST59.

The drug resistance of *S. aureus* has attracted great attention worldwide, especially in China, due to the abuse of antibiotics and the recent emergence of MDR bacteria. Consistent with a previous report ([@B50]), we show that *S. aureus* isolates exhibited a high rate of resistance to PEN, ERY, and CLI, which may be the result of the excessive use of PEN and macrolides ([@B51]). The current study demonstrated that *S. aureus* was more susceptible to vancomycin and linezolid, and displayed 100% sensitivity to vancomycin, linezolid, macrodantin, and QDA. Similarly, relatively low rates of resistance to CIP and LEV were observed in *S. aureus* isolates, which may be a result from the infrequent use of fluoroquinolones in pediatric patients due to their reported cartilage toxicity. In addition, *S. aureus* strains can differ in their antibiotic resistance patterns with specific STs. CC59 (ST59 and ST338) exhibited the highest MDR rate and a specific antibiotic resistance pattern (ERY-CLI-TE), while another common clone, CC45 (ST45), exhibited a different antibiotic resistance pattern (ERY-CLI-RIF). ST45 resistance or intermediate resistance to RIF is caused by *rpo*B mutations ([@B52]). However, strains assigned to the same cluster seemed to have similar resistance patterns, suggesting that further genotyping of the *S. aureus* strains may assist in designing more effective clinical treatment regimens.

Certain limitations were noted within this study. Firstly, more detailed clinical information was difficult to obtain, especially for outpatients, which account for the majority of patients; therefore, the study was limited in its ability to analyze the effect of additional risk factors for *S. aureus* carriage or MRSA colonization, including premature birth, duration of hospital stay, mother carriage status, history of antibiotic intake, etc. Secondly, inpatient status is strongly correlated with the carriage of MRSA; however, due to the diversity of the hospital environment, we were unable to differentiate MRSA strains based on the various areas in which the inpatients were admitted to; the source of MRSA is worth exploring further. Lastly, we only applied a single method for *S. aureus* typing, which limited access to more specific and detailed prevalent molecular characterization of *S. aureus*.

In summary, the *S. aureus* carriage rate in pediatric feces in Southern China was as high as 20%. MSSA and MRSA exhibited significant differences in genotyping and antimicrobial susceptibility, with ST59 and ST45 emerging as two major MRSA clones and ST188 as the most prevalent MSSA clone. Antibiotic resistance patterns of *S. aureus* were also found to be closely associated with specific STs. These findings clarify the colonization dynamics and molecular epidemiology of *S. aureus* from child feces in Southern China and suggest an urgent need to strengthen the surveillance programs in this region, while also providing important information regarding the prevention and treatment of *S. aureus* infection.
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